Which targeted therapies should we be more cautious of giving after recent immunotherapy in NSCLC?
Do you ever consider bridging with chemotherapy, and if so for how long?
Answer from: Medical Oncologist at Academic Institution
In general, one should be cautious. Phenomenon of increased toxicity with immune checkpoint inhibitors (ICIs) plus targeted therapies such as EGFR TKI (pneumonitis, hepatotoxicity or dermatologic toxicity), ALK TKIs (mostly hepatotoxicity) or BRAF inhibitors (hepatotoxicity, dermatologic) were ...
Sign in or Register to read more